New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:02 EDTSQNM, DGXSequenom and Quest Diagnostics announce collaboration agreement
Sequenom (SQNM) and Quest Diagnostics (DGX) announced an agreement under which Quest will offer national access to Sequenom Laboratories' MaterniT21 PLUS laboratory-developed test. Using a maternal blood sample, the noninvasive prenatal test analyzes chromosomal material in cell-free fetal DNA of pregnant women at increased risk for fetal chromosomal abnormalities. Quest expects to begin offering access to the test in the third quarter. In addition, Quest has formed a license agreement with Sequenom for certain NIPT patents and patent applications. The license agreement is the first formed by Sequenom with a commercial lab in the United States. Quest intends to use the intellectual property for the purposes of developing and validating its own proprietary lab-developed NIPT test. Quest expects to introduce this new offering in 2015. Additional terms of the agreement were not disclosed.
News For SQNM;DGX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
07:08 EDTDGXQuest Diagnostics backs FY15 adjusted EPS view $4.70-$4.85, consensus $4.78
Subscribe for More Information
07:06 EDTDGXQuest Diagnostics reports Q1 adjusted EPS $1.05, consensus $1.04
Subscribe for More Information
April 22, 2015
15:50 EDTDGXNotable companies reporting before tomorrow's open
Subscribe for More Information
April 21, 2015
08:14 EDTDGXQuest Diagnostics and Inserm launch BRCA Share initiative
Quest Diagnostics (DGX) and Inserm, the French National Institute of Health and Medical Research institution, launched BRCA Share, a novel datashare initiative they co-founded to provide scientists and laboratory organizations around the world with open access to BRCA1 and BRCA2 genetic data. The program's goal is to accelerate research on BRCA gene mutations, particularly variants of uncertain significance, to improve the ability of clinical laboratory diagnostics to predict which individuals are at risk of developing hereditary breast and ovarian cancers. Laboratory Corporation of America Holdings (LH) is the first participant in the initiative, which is structured as a user group. B
06:40 EDTDGXStart-up to offer saliva test for breast cancer susceptibility, NY Times says
Subscribe for More Information
April 15, 2015
12:32 EDTDGXFocus Diagnostics announced FDA clearance for Simplexa Group A Strep Direct Kit
Subscribe for More Information
April 13, 2015
10:15 EDTSQNMHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use